SEARCH RESULTS FOR: (*One Satoshitg:(@hkotccc)tFIg*)(458722 results)

Export results
Only the first 10,000 results were returned. Filter these results or refine your query. Some pre-built queries with more than 10,000 results are available for download.
Company Name Brand Name GMDN Term Name GMDN Term Status FDA Product Code Name FDA Product Code Device Packaged As Sterile Sterilization Prior To Use Issuing Agency Device Size Device Size Type Device Class Implantable

Show Filters

The Hemostasis BoneSeal Bone Hemostat stops bone bleeding by establishing a physical barrier along the edges of bones that have been damaged by trauma or cut during a surgical procedure. When applied as directed, BoneSeal forms a mechanical barrier that occludes the vascular openings in the damaged bone. This barrier prevents further bleeding during the surgical procedure. BoneSeal is based upon known biodegradable polymeric chemistry that forms a ready-to-use hemostatic agent. BoneSeal is available as a bone hemostat ingot of various masses. The bone hemostat ingot can be molded and formed by the surgeon to fit the damaged bone and applied to the bleeding area.
HEMOSTASIS, LLC
9550034
In Commercial Distribution

  • 00858439001514 ()
  • 00858439001521 ()

  • Weight: 3.5 Gram


  • Bone wax, synthetic
STRATOFUSE is a sterile bone graft composed of purified fibrillar type I collagen and 60% hydroxyapatite - 40% tricalcium phosphate resorbable granules. This device, formulated as a block (strip), is safe and has excellent biocompatibility. After it is implanted, the graft resorbs and is later replaced by natural bone. STRATOFUSE is indicated for use in bony voids or gaps that are not intrinsic to the stability of the bony structure. The product should be gently packed into bony voids or gaps of the skeletal system (i.e., the extremities, posterolateral spine and pelvis). These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. The product provides a bone void filler that resorbs and is replaced by the growth of new bone during the healing process. In weight bearing situations, the graft is to be used in conjunction with internal or external fixation devices. The fracture defect treated should not exceed 30ml.
BERKELEY ADVANCED BIOMATERIALS, LLC
BA41-501005
In Commercial Distribution

  • 00858418003980 ()
BA41-501005

  • Bone matrix implant, composite
STRATOFUSE is a sterile bone graft composed of purified fibrillar type I collagen and 60% hydroxyapatite - 40% tricalcium phosphate resorbable granules. This device, formulated as a block (strip), is safe and has excellent biocompatibility. After it is implanted, the graft resorbs and is later replaced by natural bone. STRATOFUSE is indicated for use in bony voids or gaps that are not intrinsic to the stability of the bony structure. The product should be gently packed into bony voids or gaps of the skeletal system (i.e., the extremities, posterolateral spine and pelvis). These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. The product provides a bone void filler that resorbs and is replaced by the growth of new bone during the healing process. In weight bearing situations, the graft is to be used in conjunction with internal or external fixation devices. The fracture defect treated should not exceed 30ml.
BERKELEY ADVANCED BIOMATERIALS, LLC
BA41-501002
In Commercial Distribution

  • 00858418003973 ()
BA41-501002

  • Bone matrix implant, composite
The Putty Convenience Kit (PCK) is a flexible polymer mat with cavities that allows the physician to mold bone putty into beads.
BERKELEY ADVANCED BIOMATERIALS, LLC
PCK-10
In Commercial Distribution

  • 00858418003959 ()
PCK-10

  • Orthopaedic cement spacer mould
EvoGraft is a sterile bone graft composed of purified fibrillar Type I collagen and 60% hydroxyapatite - 40% tricalcium phosphate resorbable granules. This device is safe and has excellent biocompatibility. After it is implanted, the graft resorbs and is later replaced by natural bone. EvoGraft is indicated for use in bony voids or gaps that are not intrinsic to the stability of the bony structure. The product should be gently packed into bony voids or gaps of the skeletal system (i.e., the extremities, posterolateral spine and pelvis). These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. The product provides a bone void filler that resorbs and is replaced by the growth of new bone during the healing process. In weight bearing situations, the graft is to be used in conjunction with internal or external fixation devices. The fracture defect treated should not exceed 30 ml.
BERKELEY ADVANCED BIOMATERIALS, LLC
EBF1-100X25-15
In Commercial Distribution

  • 00858418003935 ()
EBF1-100X25-15

  • Bone matrix implant, composite
EvoGraft is a sterile bone graft composed of purified fibrillar Type I collagen and 60% hydroxyapatite - 40% tricalcium phosphate resorbable granules. This device is safe and has excellent biocompatibility. After it is implanted, the graft resorbs and is later replaced by natural bone. EvoGraft is indicated for use in bony voids or gaps that are not intrinsic to the stability of the bony structure. The product should be gently packed into bony voids or gaps of the skeletal system (i.e., the extremities, posterolateral spine and pelvis). These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. The product provides a bone void filler that resorbs and is replaced by the growth of new bone during the healing process. In weight bearing situations, the graft is to be used in conjunction with internal or external fixation devices. The fracture defect treated should not exceed 30 ml.
BERKELEY ADVANCED BIOMATERIALS, LLC
EBF1-100X25-10
In Commercial Distribution

  • 00858418003928 ()
EBF1-100X25-10

  • Bone matrix implant, composite
EvoGraft is a sterile bone graft composed of purified fibrillar Type I collagen and 60% hydroxyapatite - 40% tricalcium phosphate resorbable granules. This device is safe and has excellent biocompatibility. After it is implanted, the graft resorbs and is later replaced by natural bone. EvoGraft is indicated for use in bony voids or gaps that are not intrinsic to the stability of the bony structure. The product should be gently packed into bony voids or gaps of the skeletal system (i.e., the extremities, posterolateral spine and pelvis). These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. The product provides a bone void filler that resorbs and is replaced by the growth of new bone during the healing process. In weight bearing situations, the graft is to be used in conjunction with internal or external fixation devices. The fracture defect treated should not exceed 30 ml.
BERKELEY ADVANCED BIOMATERIALS, LLC
EBF1-90X22-07
In Commercial Distribution

  • 00858418003911 ()
EBF1-90X22-07

  • Bone matrix implant, composite
EvoGraft is a sterile bone graft composed of purified fibrillar Type I collagen and 60% hydroxyapatite - 40% tricalcium phosphate resorbable granules. This device is safe and has excellent biocompatibility. After it is implanted, the graft resorbs and is later replaced by natural bone. EvoGraft is indicated for use in bony voids or gaps that are not intrinsic to the stability of the bony structure. The product should be gently packed into bony voids or gaps of the skeletal system (i.e., the extremities, posterolateral spine and pelvis). These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. The product provides a bone void filler that resorbs and is replaced by the growth of new bone during the healing process. In weight bearing situations, the graft is to be used in conjunction with internal or external fixation devices. The fracture defect treated should not exceed 30 ml.
BERKELEY ADVANCED BIOMATERIALS, LLC
EBF1-90X22-10
In Commercial Distribution

  • 00858418003904 ()
EBF1-90X22-10

  • Bone matrix implant, composite
EvoGraft is a sterile bone graft composed of purified fibrillar Type I collagen and 60% hydroxyapatite - 40% tricalcium phosphate resorbable granules. This device is safe and has excellent biocompatibility. After it is implanted, the graft resorbs and is later replaced by natural bone. EvoGraft is indicated for use in bony voids or gaps that are not intrinsic to the stability of the bony structure. The product should be gently packed into bony voids or gaps of the skeletal system (i.e., the extremities, posterolateral spine and pelvis). These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. The product provides a bone void filler that resorbs and is replaced by the growth of new bone during the healing process. In weight bearing situations, the graft is to be used in conjunction with internal or external fixation devices. The fracture defect treated should not exceed 30 ml.
BERKELEY ADVANCED BIOMATERIALS, LLC
EBF2-50X25-10
In Commercial Distribution

  • 00858418003898 ()
EBF2-50X25-10

  • Bone matrix implant, composite
EvoGraft is a sterile bone graft composed of purified fibrillar Type I collagen and 60% hydroxyapatite - 40% tricalcium phosphate resorbable granules. This device is safe and has excellent biocompatibility. After it is implanted, the graft resorbs and is later replaced by natural bone. EvoGraft is indicated for use in bony voids or gaps that are not intrinsic to the stability of the bony structure. The product should be gently packed into bony voids or gaps of the skeletal system (i.e., the extremities, posterolateral spine and pelvis). These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. The product provides a bone void filler that resorbs and is replaced by the growth of new bone during the healing process. In weight bearing situations, the graft is to be used in conjunction with internal or external fixation devices. The fracture defect treated should not exceed 30 ml.
BERKELEY ADVANCED BIOMATERIALS, LLC
EBF1-50X10-02
In Commercial Distribution

  • 00858418003874 ()
EBF1-50X10-02

  • Bone matrix implant, composite
< 1 ... 289 290 291 292 293 ... 1000 >